Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Diaa Youssef
 -- 2632 2022-11-14 19:57:51 |
2 Format correction
Sirius Huang
 + 1 word(s) 2633 2022-11-15 02:26:21 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Youssef, D.T.A.;  Shaala, L.A. Pharmacological Properties of Psammaplysins. Encyclopedia. Available online: https://encyclopedia.pub/entry/34497 (accessed on 18 November 2024).
Youssef DTA,  Shaala LA. Pharmacological Properties of Psammaplysins. Encyclopedia. Available at: https://encyclopedia.pub/entry/34497. Accessed November 18, 2024.
Youssef, Diaa T. A., Lamiaa A. Shaala. "Pharmacological Properties of Psammaplysins" Encyclopedia, https://encyclopedia.pub/entry/34497 (accessed November 18, 2024).
Youssef, D.T.A., & Shaala, L.A. (2022, November 14). Pharmacological Properties of Psammaplysins. In Encyclopedia. https://encyclopedia.pub/entry/34497
Youssef, Diaa T. A. and Lamiaa A. Shaala. "Pharmacological Properties of Psammaplysins." Encyclopedia. Web. 14 November, 2022.
Pharmacological Properties of Psammaplysins
Edit
This entry is adapted from the peer-reviewed paper 10.3390/md20110663

Marine natural products (MNPs) continue to be in the spotlight in the global drug discovery endeavor. Currently, more than 32,000 structurally diverse secondary metabolites from marine sources have been isolated, making MNPs a vital source for researchers to look for novel drug candidates. The marine-derived psammaplysins possess the rare and unique 1,6-dioxa-2-azaspiro [4.6] undecane backbone and are represented by 44 compounds in the literature, mostly from sponges of the order Verongiida.

marine alkaloids 1,6-dioxa-2-azaspiro[4.6]undecane backbone psammaplysins

1. Introduction

Marine invertebrates are the most diverse group of marine life that exist in the oceans with highest biological and chemical diversity. A total of 38,925 marine-derived natural products, published in 38,645 articles, were identified from marine organisms [1]. Such chemical biodiversity is attributed to the fact that these compounds are produced by mostly sessile organisms present in the marine environment. These sessile organisms are extremely susceptible to be attacked by predators. Marine invertebrates, such as sponges, tunicates, bryozoans, gorgonians, and soft corals evolve chemicals as a defense mechanism against highly mobile predators. Marine sponges are one of the most productive phyla of marine invertebrates and considered as an outstanding source of biologically active secondary metabolites [2].
Members of the Phylum Porifera and their associated microbes represent the largest reservoir and supplier of secondary metabolites. Primitive and sessile animals, such as sponges, developed survival strategies depending on the production of defensive secondary metabolites for their own protection against different predators, fouling organisms, and invasion by different microbes and pathogens. Sponges are classified in four major classes including Calcarea, Demospongiae, Hexactinellida, and Homoscleromorpha. The chemical structural diversity of the secondary metabolites of the sponges includes several classes, such as alkaloids, macrolides, peptides, steroids, terpenoids, polyketides, and many others. [3].
It was proven that the sponge-derived secondary metabolites produce an enormous array of antitumor, antiviral, anti-inflammatory, antibiotic, and other bioactive molecules that have the potential for therapeutic use. Studies have shown that different compounds affect the targeted disease through different modes of action. Chemical entities that can act as transcription factor inhibitors may be effective against both viral infections and malignant neoplasms. Most bioactive metabolites from sponges have proven to inhibit specific enzymes, which often mediate or produce mediators of intercellular or intracellular messengers involved in the development of diseases [4].
Amongst different orders of marine sponges, the order Verongiida is considered as a reservoir of brominated tyrosine-derived secondary metabolites. This order belongs to the kingdom Animalia, phylum Porifera, class Demospongia, and subclass Verongimorpha. According to the World Porifera Database, order Verongiida includes five families viz. Aplysinellidae, Ernstillidae, Aplysinidae, Ianthellidae, and Pseudoceratinidae.
Members of the order Verongiida attracted researchers of the marine natural products community over the past 65 years due to the large number of bioactive bromotyrosine-derived alkaloids that they produce [2]. Bromotyrosine-derived alkaloids display significant chemical diversity and offer effective chemical defense for these organisms against predators in the ocean [5][6] and the fouling organisms [7][8].
Bromotyrosine derivatives of the order Verongiida include several classes, such as spirooxepinisoxazolines, mono- and bis-configurated spiroisoxazolines, dibromocyclohexadienes, brominated phenolics, verongiaquinols, verongiabenzenoids, oxime disulfides, brominated oximes, bromotyramines, bromotyramine oximes, bastadins, and hemibastadins. Additional chemical classes that are not of bromotyrosine biosynthetic origin in this order are indole alkaloids, pyrroles, quinolines, hydroquinones guanidines, benzofurans isoprenoids, benzonaphthyridines, sesquiterpenoids, sesterterpenoids, merosesquiterpenoids, and macrolides [9].
The bromotyrosine-derived compounds are considered as a class of interest due to their structural diversity and pharmacological and biological importance [10][11][12][13]. Prominent members of the bromotyrosine derivatives include psammaplins, disulfide-linked compounds, that were first isolated from an unidentified specimen of Psammaplysilla Keller, 1889 (=Pseudoceratina Carter, 1885) [14]. These compounds have stimulated further and deeper investigations on other Verongiid sponges as well as the synthesis of targeted anti-cancer drug analogs [15][16][17]. The bromotyrosin-derived compounds of the Verongiid sponges display huge pharmaceutical and biomedical potential, with many viewed as being promising targets within the preclinical pipeline. Preclinical assays on bromotyrosines have highlighted many candidates for antiplasmodial [18][19], antimicrobial [19][20][21][22][23][24][25][26][27][28][29], antioxidant [24][25], anti-invasion, and antimigratory [30][31][32], parasympatholytic [33], as well as compounds that affect the central nervous system [20][26][34][35]. These significant and broad-spectrum activities have provided much motivation for further investigations of the members of this order for the exploration of its secondary metabolites and biomedical importance.
To date, more than 633 natural products, mostly bromotyrosine-derived, are reported from over 43 different species of the order Verongiida in the literature [9]. Among these, forty-one bromotyrosine alkaloids possessing the 1,6-dioxa-2-azaspiro [4.6] undecane skeleton have been reported from marine sponges of the Verongiida, including members of genera Aplysinella, Psammaplysilla, Pseudoceratina, and Subarea, and three compounds from the order Dictyoceratida (including the genera Dysidea and Hyattella).

2. Compounds with Antimicrobial Properties

Psammaplysins A (1) and B (2) have been reported to show in vitro activity towards gram positive bacteria as well as E. coli [36]. In addition, psammaplysin A (1) has found to possess antibacterial activity against Flavobacterium marinotypicum with an inhibition zone of 10 mm at a concentration of 10 µg/disc [37]. Furthermore, Psammaplysins A (1) and B (2) have been described to inhibit the Mycobacterium tuberculosis detoxification enzyme mycothiol-S-conjugate amidase in a fluorescence-detected assay [38]. Furthermore, psammaplysins F (10) and H (12) have been found to inhibit the growth of six Gram-positive strains, S. aureus NCTC 6571, S. aureus 1H, E. facecalis NCTC-775, B. cereus NCTC-7464, MRSA MW2 and MRSA USA-300 [38] (Table 1).
Table 1. Compounds with reported antimicrobial activities.
Compounds Antimicrobial Activity Reference
Psammaplysin A (1) In vitro activity against gram positive bacteria and E. coli
Antibacterial activity against Flavobacterium marinotypicum
Inhibits mycothiol-S-conjugate amidase of Mycobacterium tuberculosis with IC50 of 20 µM		 [36][37][38]
Psammaplysin B (2) In vitro activity against Gram-positive bacteria and E. coli
Inhibits mycothiol-S-conjugate amidase of Mycobacterium tuberculosis with IC50 of 26 µM		 [36][38]
Psammaplysin F (10) Inhibits the growth of S. aureus NCTC 6571, S. aureus 1H, E. facecalis NCTC-775, B. cereus NCTC-7464, MRSA MW2 and MRSA USA-30050 with MIC values of 42.8, 42.8, 42.8, 42.8, 40.0, and 80.0 µM [39]
Psammaplysin (12) Inhibits the growth of S. aureus NCTC 6571, S. aureus 1H, E. facecalis NCTC-775, B. cereus NCTC-7464, MRSA MW2 and MRSA USA-30050 with MIC values of 20.4, 45.0, 81.5, 81.5, 40.0, and 80.0 µM [39]

3. Compounds with Growth Inhibition and Cytotoxic Activities

Psammaplysin A (1) has been reported as a growth inhibitor of many cancer cell lines including, HCT-116, HCT-15 (colon cancer), PC-3 (prostate cancer), ACHN (renal cancer), MDA-MB-231 (breast cancer), NUGC-3 (stomach cancer), NCI-H23 (lung cancer), and Hela (Cervical) [40][41][42][43] (Table 2).
Table 3. Compounds with reported cancer cells’ growth inhibition activities.
Compounds Cytotoxicity Reference
Psammaplysin A (1) - Inhibits HCT-116 with an IC50 of 6 µg/mL
- Inhibits HCT-15, PC-3, ACHN, MDA-MB-231, NUGC-3 and NCI-H23 with GI50 values 3.9, 6.9, 5.1, 4.3, 3.8, and 12.4 µM, respectively
- Inhibits MDA-MB-231 and Hela cells with IC50 values of 2.9 and 8.5 µM respectively
- Inhibits HCT116, MDA-MB-231, and Hela cells with IC50 values of 5.1, 3.90, and 8.50 respectively		 [40][41][42][43]
Psammaplysin B (2) - Inhibits HCT-116 with IC50 value of 6 µg/mL
- Inhibited HCT-15, PC-3, ACHN, MDA-MB-231, NUGC-3, and NCI-H23 with GI50 values of 4.0, 2.7, 1.6, 0.53, 2.5, and 3.7 µM, respectively		 [41][42]
Psammaplysin C (3) Inhibits HCT-116 with IC50 of 3 µg/mL [41]
Psammaplysin D (4) - Weak growth inhibition of HCT-15, PC-3, ACHN, MDA-MB-231, NUGC-3, and NCI-H23 with GI50 values 24, 25, 27, 21, 26, and 27 µM, respectively [42]
Psammaplysin E (5) - Inhibited KB and LoVo cells at 5 µg/mL
- Inhibited P388 cell with IC50 of 2.1 µg/mL
- Inhibited HCT-15, PC-3, ACHN, MDA-MB-231, NUGC-3, and NCI-H23 cells with GI50 values 3.8, 1.4, 2.3, 0.51, 2.3, and 3.6 µM, respectively
- Antimigratory activity against MDA-MB-231 and Hela cells with IC50 values of 0.29 and 2.1 µM, respectively		 [37][40][42][44]
Psammaplysin F (10) Inhibits HEK293 mammalian cell line with IC50 value of 11 μM [45]
Psammaplysin X (35) Inhibits HCT-15, PC-3, ACHN, MDA-MB-231, NUGC-3, and NCI-H23 cells with GI50 values of 3.3, 2.3, 3.3, 1.2, 3.5, and 6.4 µM, respectively [42]
19-Hydroxypsammaplysin X (36) Inhibits HCT-15, PC-3, ACHN, MDA-MB-231, NUGC-3, and NCI-H23 cells with GI50 values of 3.5, 2.1, 2.5, 0.8, 4.0, and 3.5 µM, respectively [42]
Psammaplysin Z (38) Inhibits MDA-MB-231 and Hela cell lines with IC50 values 19.4 and 22.2 µM, respectively [40]
19-Hydroxypsammaplysin Z (39) Inhibits MDA-MB-231 and Hela cell lines with IC50 values of 13.2 and 17.6 µM, respectively [40]
Psammaceratin A (44) Inhibits MDA-MB-231, Hela, and HCT116 cells with IC50 values of 5.25, 9.40, and 3.10 µM, respectively [43]
Similarly, psammaplysin B (2) was found to inhibit the growth of several cell lines, including HCT-116, HCT-15 (colon cancer), PC-3 (prostate cancer), ACHN (renal cancer), MDA-MB-231 (breast cancer), NUGC-3 (stomach cancer), and NCI-H23 (lung cancer) [41][42] (Table 2).
Psammaplysin C (3) has been reported to inhibit the growth of HCT-116 cell line [41] (Table 1). Likewise, psammaplysin D (4) has been reported to inhibit the growth of HCT-15 (colon cancer), PC-3 (prostate cancer), ACHN (renal cancer), MDA-MB-231 (breast cancer), NUGC-3 (stomach cancer), and NCI-H23 (lung cancer) cell lines [42] (Table 2).
Psammaplysin E (5) has been reported as a potent growth inhibitor of several cancer cell lines, including KB (human oral, epidermoid carcinoma), LoVo (human colon, adenocarcinoma), HCT-15, PC-3, ACHN, MDA-MB-231, NUGC-3, and NCI-H23 [37][40][42][44]. In addition, it has been found that psammaplysin E possesses a potent antimigratory effect against MDA-MB-231 and Hela cells [40] and has moderate immunosuppressive activity as well [44] (Table 2).
Psammaplysin F (10) has been reported as a moderate inhibitor of HEK293 mammalian cell line [45] (Table 2).
Psammaplysin X (35) and 19-hydroxypsammaplysin X (36) were reported to inhibit the growth of HCT-15, PC-3, ACHN, MDA-MB-231, NUGC-3, and NCI-H23 cancer cell lines [42] (Table 2).
Psammaplysin Z (38) and 19-hydroxypsammaplysin Z (39) were found to inhibit the growth of MDA-MB-231 and HeLa cancerous cell lines [40] (Table 2).
Finally, psammaceratin A (44) has been reported to inhibit the growth of MDA-MB-231, Hela, and HCT116 cell lines [43] (Table 2).
From the above results, it could be concluded that the growth inhibition of the psammaplysins towards cancerous cell lines suggests that the spirooxepinisoxazoline ring system is an essential element for the activity. The N-terminal substitution with a cyclopentene-dione moiety, as in psammaplsyins E (5) and 19-hydroxypsammaplysin E (6), or 4-chloro-2-methylenecyclopentane-1,3-dione moiety, as in psammaplysin X (35) and 19-hydroxypsammaplysin X (36), increases the activity. Further, introduction of 19-OH group, as in psammaplysin B (2) versus psammaplysin A (1), diminishes the activity (Table 2).
On the contrary, psammaplysin D (4), however, lacked activity (GI50 > 10 μM), which might be explained by its high lipophilicity. Furthermore, the existence of a terminal N-methyl group, as in psammaplysin F (10), or an urea moiety, as in psammaplysin Z (38), diminished the growth inhibition effect (Table 2).

4. Compounds with Antimalarial Activities

19-Hydroxypsammaplysin E (6), psammaplysin K (15), psammaplysin L (17), psammaplysin M (18), psammaplysin N (19), 19-hydroxypsammaplysin P (22), psammaplysin T (28), and psammaplysin V (32) have been evaluated for their antimalarial activity, at 10 μM, against the chloroquine-sensitive Plasmodium falciparum 3D7 malaria parasite line. Only 19-hyroxypsammaplysin E (6) was found to have antimalarial effect against this strain [46] (Table 3).
Table 3. Compounds with reported antimalarial activities.
Compound Activity Reference
19-Hydroxypsammaplysin E (6) Inhibits 3D7 chloroquine-sensitive strain of P. falciparum with IC50 of 6.4 μM [46]
Psammaplysin F (10) - Inhibits 3D7 and Dd2 strains of P. falciparum with IC50 values of 0.87 and 1.4 μM
- Inhibits the drug-resistant (K1) and drug-sensitive (FCR3) strains of P. falciparum with IC50 values of 3.77 and 2.45 µg/mL and with selectivity indices of 3.4 and 5.2, respectively		 [45][47]
Psammaplysin G (11) Inhibits 98% of Dd2 cell strain of P. falciparum at 40 μM [45]
Psammaplysin H (12) Inhibits the 3D7 strain of P. falciparum with an IC50 value of 0.41 µM and selective towards the 3D7 strain of P. falciparum with a selectivity index (SI) of >97% [48]
Ceratinadin E (40) Inhibits K1 and FCR3 strains of P. falciparum, with IC50 values of 1.03 and 0.77 μg/mL, respectively and with selectivity indices (SI) of 15.5 and 20.8, respectively [47]
Ceratinadin F (41) Inhibits K1 strain of P. falciparum with an IC50 >12.5 μg/mL and selectivity index (SI) value of >4 [47]
Similarly, psammaplysin F (10) has been reported to inhibit chloroquine-sensitive (3D7), Dd2 [45], the drug-resistant (K1) and drug-sensitive (FCR3) strains of P. falciparum [47] (Table 3). Furthermore, psammaplysin G (11) has been found to inhibit the chloroquine-resistant (Dd2) P. falciparum strain without any toxicity towards the HEK293 cell line [45]. Likewise, psammaplysin H (12) was described to have a potent antiplasmodial activity against 3D7 strain with an excellent selectivity index [48] (Table 3).
Finally, ceratinadins E (40) and F (41) were reported to show antiplasmodial activities against the drug-resistant (K1) and drug-sensitive (FCR3) strains of P. falciparum. Moreover, ceratinadin E (40) was found to display higher selectivity indices (SI) than ceratinadin F (41) [47] (Table 3).
The antimalarial evaluation of 13 psammaplysins analogs clearly shows that psammaplysin F (10) is the most potent active compound against Dd2 strain, while ceratinadin E (40) possesses a greater antimalarial activity towards K1 strain and a better selectivity index than psammaplysins F (10). The addition of a terminal N-methyl, as in psammaplysin F (10), enhances the activity. However, ceratinadin F (41), which possesses several N-methyls, did not show significant antimalarial activity, which could be attributed to the high lipophilicity of the compound. Though the antimalarial activity against drug-resistant strains of P. falciparum is unknown, psammaplysin H (12), a quaternary analog with a trimethylamino group instead of a methylamino group, possesses a potent antimalarial activity and better selectivity against a drug-sensitive strain of P. falciparum than psammaplysins F (10) without any significant cytotoxicity against the HEK293 384 cell line [45][46][48] (Table 3).
Comparing the activities of psammaplysins F (10), G (11), and H (12) towards two mammalian cell lines (HEK293 and HepG2), psammaplysin H was found to display a minimal toxicity at the highest concentration tested (40 μM), giving this compound a parasite-specific selectivity index (SI) of >97. In contrast, psammaplysins G and F display higher toxicity to these cell lines with IC50 values between 3.71 and 18.96 μM, respectively. These preliminary structure–activity data suggest that full methyl-substitution of the terminal amine (N-quaternization) is essential for optimal antimalarial activity and better selectivity [48].
Likewise, the replacement of an urea, amine, or enamine derivative with a secondary amide group adversely affects the antimalarial activity. However, the higher lipophilicity (i.e., log P) and larger molecular weights associated with the amide analogs including psammaplysin M (18), psammaplysin N (19), 19-hyroxypsammaplysin P (22), psammaplysin T (29, and psammaplysin V (32) would also minimize the bioavailability [49], thus reducing the antimalarial effect.

5. Compounds with Antifouling Activities

When evaluated for their antifouling activity, psammaplsyins A (1), E (5), ceratinamides A (7) and B (8) have reported to inhibit the metamorphosis and settlement of the barnacle B. Amphitrite [37] (Table 4). The highest activities of psammaplysin A (1) and ceratinamide A (7) suggests the importance of a terminal amine or an N-formyl moiety for a maximum antifouling activity. Furthermore, ceratinamide A (7) was found to induce a larval metamorphosis of the ascidian Halocynthia roretzi [37] (Table 4).
Table 4. Compounds with reported antifouling activities.
Compound Activity Reference
Psammaplysin A (1) Inhibits metamorphosis and settlement of B. amphitrite with an ED50 0.27 µg/mL [37]
Psammaplysin E (5) Inhibits metamorphosis and settlement of B. amphitrite with an ED50 4.8 µg/mL [37]
Ceratinamide A (7) Inhibits metamorphosis and settlement of B. amphitrite with an ED50 0.10 µg/mL
Induces metamorphosis on the ascidian Halocynthia roretzi with ED100 of 1.2 µg/mL		 [37]
Ceratinamide B (8) Inhibits metamorphosis and settlement of B. amphitrite with an ED50 2.4 µg/mL [37]

6. Compounds with Other Reported Activities

Psammaplysin D (4) was reported to display anti-HIV towards the Haitian RF strain of HIV-I [44] (Table 4). Recently, psammaplysin F (10) was reported to increase the efficacy of the antitumor drugs bortezomib and sorafenib through regulation of the synthesis of stress granules [50] (Table 5).
Table 5. Compounds with other reported activities.
Compound Activity Reference
Psammaplysin D (4) Inhibits 51% of the Haitian RF strain of HIV-I at 0.1 µg/mL [44]
Psammaplysin E (5) Moderate immunosuppressive activity with a potency of 40, ICW = 8.323-01 for mixed lymphocyte reaction assay [44]
Frondoplysin A (42) - Inhibits protein tyrosine phosphatase 1B with an IC50 value of 0.39 μM compared to oleanolic acid as a positive control (IC50 3.7 μM) and thiazolidinediones (IC50 5.0 μM) similar to benzofuran and benzothiophene biphenyls (IC50 0.36 μM)
- Antioxidant activity in transgenic zebrafish without any cytotoxicity at 64 μM		 [51]
Frondoplysin B (43) Inhibits protein tyrosine phosphatase 1B with an IC50 value of 0.65 μM compared to oleanolic acid as a positive control (IC50 3.7 μM) [51]
Psammaplysin F (10) and its urea semisynthetic analogs 45, 51, 53 and 54 Reduce the mitochondrial membrane potential (MMP) [52]
Frondoplysins A (42) and B (43) were described to inhibit protein-tyrosine phosphatase IB (PTP1B). The compounds were found to have a higher activity than the positive control oleanolic acid [51] and thiazolidinediones [53] and were similar to benzofuran and benzothiophene biphenyls [54] (Table 5). Further, frondoplysin A was found to possess in vivo antioxidant activity in transgenic fluorescent zebrafish over five times stronger than that of vitamin C [51] without any cytotoxicity [51] (Table 5).
It has been described that psamaplysin F (10) andits urea semisynthetic analogs (45, 51, 53 and 54) strongly reduce the mitochondrial membrane potential (MMP). Further, it was found that psammaplysin F strongly affects the mitochondrial morphology and reduced the number of end points and branch points within the tubular structure of individual mitochondria, leading to visible fragmentation of the mitochondrial tubular network. These findings provide a strong rationale for more detailed mechanistic studies of psammaplysin F and derivatives as novel mitochondrial poisons [52].

References

  1. Available online: https://marinlit.rsc.org/ (accessed on 19 July 2022).
  2. Carroll, A.R.; Copp, B.R.; Davis, R.A.; Keyzers, R.A.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2022, 39, 1122–1171.
  3. Han, B.-N.; Hong, L.-L.; Gu, B.-B.; Yang-Ting Sun, Y.-T.; Wang, J.; Liu, J.-T.; Lin, H.-W. Natural Products from Sponges. In Symbiotic Microbiomes of Coral Reefs Sponges and Corals; Li, Z., Ed.; Springer Nature B.V.: Dordrecht, The Netherland, 2019; Chapter 15; pp. 329–463.
  4. Blunt, J.W.; Copp, B.R.; Keyzers, R.A.; Munro, M.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2013, 30, 237–323.
  5. Thoms, C.; Schupp, P.J. Activated chemical defense in marine sponges—A case study on Aplysinella rhax. J. Chem. Ecol. 2008, 34, 1242–1252.
  6. Thoms, C.; Wolff, M.; Padmakumar, K.; Ebel, R.; Proksch, P. Chemical defense of Mediterranean sponges Aplysina cavernicola and Aplysina aerophoba. Z. Naturforsch. 2004, 59, 113–122.
  7. Ortlepp, S.; Sjogren, M.; Dahlstrom, M.; Weber, H.; Ebel, R.; Edrada, R.; Thoms, C.; Schupp, P.; Bohlin, L.; Proksch, P. Antifouling activity of bromotyrosine-derived sponge metabolites and synthetic analogues. Mar. Biotechnol. 2007, 9, 776–785.
  8. Teeyapant, R.; Woerdenbag, H.J.; Kreis, P.; Hacker, J.; Wray, V.; Witte, L.; Proksch, P. Antibiotic and cytotoxic activity of brominated compounds from the marine sponge Verongia aerophoba. Z. Naturforsch. 1993, 48, 939–945.
  9. Lever, J.; Brkljača, R.; Rix, C.; Urban, S. Application of networking approaches to assess the chemical diversity, biogeography, and pharmaceutical potential of Verongiida natural products. Mar. Drugs 2021, 19, 582.
  10. Peng, J.; Li, J.; Hamann, M.T. The marine bromotyrosine derivatives. Alkaloids Chem. Biol. 2005, 61, 59–262.
  11. Lira, N.S.; Montes, R.C.; Tavares, J.F.; da Silva, M.S.; da Cunha, E.V.; de Athayde-Filho, P.F.; Rodrigues, L.C.; da Silva Dias, C.; Barbosa-Filho, J.M. Brominated compounds from marine sponges of the genus Aplysina and a compilation of their 13C NMR spectral data. Mar. Drugs 2011, 9, 2316–2368.
  12. El-Demerdash, A.; Atanasov, A.G.; Horbanczuk, O.K.; Tammam, M.A.; Abdel-Mogib, M.; Hooper, J.N.A.; Sekeroglu, N.; Al-Mourabit, A.; Kijjoa, A. Chemical diversity and biological activities of marine sponges of the genus Suberea: A systematic review. Mar. Drugs 2019, 17, 115.
  13. Niemann, H.; Marmann, A.; Lin, W.; Proksch, P. Sponge derived bromotyrosines: Structural diversity through natural combinatorial chemistry. Nat. Prod. Comm. 2015, 10, 219–231.
  14. Quinoa, E.; Crews, P. Phenolic constituents of psammaplysilla. Tetrahedron Lett. 1987, 28, 3229–3232.
  15. Jing, Q.; Hu, X.; Ma, Y.; Mu, J.; Liu, W.; Xu, F.; Li, Z.; Bai, J.; Hua, H.; Li, D. Marine-derived natural lead compound disulfide-linked dimer psammaplin A: Biological activity and structural modification. Mar. Drugs 2019, 17, 384.
  16. Kumar, M.S.L.; Ali, K.; Chaturvedi, P.; Meena, S.; Datta, D.; Panda, G. Design, synthesis and biological evaluation of oxime lacking psammaplin inspired chemical libraries as anti-cancer agents. J. Mol. Struct. 2021, 1225, 129173.
  17. Bao, Y.; Xu, Q.; Wang, L.; Wei, Y.; Hu, B.; Wang, J.; Liu, D.; Zhao, L.; Jing, Y. Studying histone deacetylase inhibition and apoptosis induction of psammaplin A monomers with modified thiol group. ACS Med. Chem. Lett. 2021, 12, 39–47.
  18. Lebouvier, N.; Jullian, V.; Desvignes, I.; Maurel, S.; Parenty, A.; Dorin-Semblat, D.; Doerig, C.; Sauvain, M.; Laurent, D. Antiplasmodial activities of homogentisic acid derivative protein kinase inhibitors isolated from a Vanuatu marine sponge Pseudoceratina sp. Mar. Drugs 2009, 7, 640–653.
  19. Mayer, A.; Rodríguez, A.D.; Taglialatela-Scafati, O.; Fusetani, N. Marine pharmacology in 2009–2011: Marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous systems, and other miscellaneous mechanisms of action. Mar. Drugs 2013, 11, 2510–2573.
  20. Mayer, A.; Guerrero, A.J.; Rodríguez, A.D.; Taglialatela-Scafati, O.; Nakamura, F.; Fusetani, N. Marine pharmacology in 2014–2015: Marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis, antiviral, and anthelmintic activities; affecting the immune and nervous systems, and other miscellaneous mechanisms of action. Mar. Drugs 2020, 18, 5.
  21. Shaala, L.A.; Youssef, D.T.A. Pseudoceratonic Acid and molok’iamine derivatives from the Red Sea Verongiid sponge Pseudoceratina arabica. Mar. Drugs 2020, 18, 525.
  22. Xu, M.; Davis, R.A.; Feng, Y.; Sykes, M.L.; Shelper, T.; Avery, V.M.; Camp, D.; Quinn, R.J. Ianthelliformisamines A-C, antibacterial bromotyrosine-derived metabolites from the marine sponge Suberea ianthelliformis. J. Nat. Prod. 2012, 75, 1001–1005.
  23. Pieri, C.; Borselli, D.; Di Giorgio, C.; De Meo, M.; Bolla, J.-M.; Vidal, N.; Combes, S.; Brunel, J.M. New ianthelliformisamine derivatives as antibiotic enhancers against resistant Gram-negative bacteria. J. Med. Chem. 2014, 57, 4263–4272.
  24. Shaala, L.A.; Bamane, F.H.; Badr, J.M.; Youssef, D.T.A. Brominated arginine-derived alkaloids from the Red Sea sponge Suberea mollis. J. Nat. Prod. 2011, 74, 1517–1520.
  25. Abou-Shoer, M.I.; Shaala, L.A.; Youssef, D.T.A.; Badr, J.M.; Habib, A.M. Bioactive brominated metabolites from the Red Sea sponge Suberea mollis. J. Nat. Prod. 2008, 71, 1464–1467.
  26. Mayer, A.; Rodríguez, A.D.; Taglialatela-Scafati, O.; Fusetani, N. Marine pharmacology in 2012–2013: Marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous systems, and other miscellaneous mechanisms of action. Mar. Drugs 2017, 15, 273.
  27. Mani, L.; Jullian, V.; Mourkazel, B.; Valentin, A.; Dubois, J.; Cresteil, T.; Folcher, E.; Hooper, J.N.A.; Erpenbeck, D.; Aalbersberg, W.; et al. New antiplasmodial bromotyrosine derivatives from Suberea ianthelliformis. Chem. Biodivers. 2012, 9, 1436–1451.
  28. Buchanan, M.S.; Carroll, A.R.; Wessling, D.; Jobling, M.; Avery, V.M.; Davis, R.A.; Feng, Y.; Xue, Y.; Oster, L.; Fex, T.; et al. Clavatadine A, a natural product with selective recognition and irreversible inhibition of factor XIa. J. Med. Chem. 2008, 51, 3583–3587.
  29. Buchanan, M.S.; Carroll, A.R.; Wessling, D.; Jobling, M.; Avery, V.M.; Davis, R.A.; Feng, Y.; Hooper, J.N.A.; Quinn, R.J. Clavatadines C-E, guanidine alkaloids from the Australian sponge Suberea clavata. J. Nat. Prod. 2009, 72, 973–975.
  30. Shaala, L.A.; Youssef, D.T.A.; Badr, J.M.; Souliman, M.; Khedr, A. Bioactive secondary metabolites from a Red Sea marine Verongid sponge Suberea species. Mar. Drugs 2015, 13, 1621–1631.
  31. Shaala, L.A.; Youssef, D.T.A.; Sulaiman, M.; Behery, F.A.; Foudah, A.I.; El Sayed, K.A. Subereamolline A as a potent breast cancer migration, invasion and proliferation inhibitor and bioactive dibrominated alkaloids from the Red Sea sponge Pseudoceratina arabica. Mar. Drugs 2012, 10, 2492–2508.
  32. Shaala, L.A.; Youssef, D.T.A.; Badr, J.M.; Sulaiman, M.; Khedr, A.; El Sayed, K.A. Bioactive alkaloids from the Red Sea marine Verongid sponge Pseudoceratina arabica. Tetrahedron 2015, 71, 7837–7841.
  33. Badr, J.M.; Shaala, L.A.; Abou-Shoer, M.I.; Tawfik, M.A.; Habib, A.M. Bioactive brominated metabolites from the Red Sea sponge Pseudoceratina arabica. J. Nat. Prod. 2008, 71, 1472–1474.
  34. Feng, Y.; Bowden, B.F.; Kapoor, V. Ianthellamide A, a selective kynurenine-3-hydroxylase inhibitor from the Australian marine sponge Ianthella quadrangulata. Bioorg. Med. Chem. Lett. 2012, 22, 3398–3401.
  35. Tian, L.W.; Feng, Y.; Shimizu, Y.; Pfeifer, T.; Wellington, C.; Hooper, J.N.; Quinn, R.J. Aplysinellamides A-C, bromotyrosine-derived metabolites from an Australian Aplysinella sp. marine sponge. J. Nat. Prod. 2014, 77, 1210–1214.
  36. Rotem, M.; Carmely, S.; Kashman, Y. Two new antibiotics from the Red Sea sponge Psammaplysilla purprea. Tetrahedron 1983, 39, 667–676.
  37. Tsukamoto, S.; Kato, H.; Hirota, H.; Fusetani, N. Ceratinamides A and B: New antifouling dibromotyrosine derivatives from the marine sponge Pseudoceratina purpurea. Tetrahedron 1996, 52, 8181–8186.
  38. Nicholas, G.M.; Eckman, L.L.; Ray, S.; Hughes, R.O.; Pfefferkorn, J.A.; Barluenga, S.; Nicolaou, K.C.; Bewley, C.A. Bromotyrosine-derived natural and synthetic products as inhibitors of mycothiol-S-conjugate amidase. Bioorg. Med. Chem. 2002, 12, 2487–2490.
  39. Ramsey, D.M.; Amirul, I.M.; Turnbull, L.; Davis, R.A.; Whitchurch, C.B.; McAlpine, S.R. Psammaplysin F: A unique inhibitor of bacterial chromosomal partitioning. Bioorg. Med. Chem. Lett. 2013, 23, 4862–4866.
  40. Shaala, L.A.; Youssef, D.T.A. Cytotoxic psammaplysin analogues from Red Sea sponge Aplysinella species. Biomolecules 2019, 9, 841.
  41. Copp, B.R.; Ireland, C.M.; Barrows, R.L. Psammaplysin C: A new cytotoxic dibromotyrosine derived metabolite from the marine sponge Druinella (= Psammplysilla) purpurea. J. Nat.Prod. 1992, 55, 822–823.
  42. Lee, Y.J.; Han, S.; Lee, H.S.; Kang, J.S.; Yun, J.; Sim, C.J.; Shin, H.J.; Lee, J.S. Cytotoxic psammaplysin analogues from a Suberea sp. marine sponge and the role of the spirooxepinisoxazoline in their activity. J. Nat. Prod. 2013, 76, 1731–1736.
  43. Youssef, D.T.A.; Asfour, H.Z.; Shaala, A.L. Psammaceratin A: A cytotoxic psammaplysin dimer featuring an unprecedented (2Z,3Z)-2,3-bis(aminomethylene)succinamide backbone from the Red Sea sponge Pseudoceratina arabica. Mar. Drugs 2021, 19, 433.
  44. Ichiba, T.; Scheuer, P.J.; Kelly-Borges, M. Three bromotyrosine derivatives, one terminating in an unprecedented diketocyclopentenylidene enamine. J. Org. Chem. 1993, 58, 4149–4150.
  45. Yang, X.; Davis, R.A.; Buchanan, M.S.; Duffy, S.; Avery, V.M.; Camp, D.; Quinn, R.J. Antimalarial bromotyrosine derivatives from the Australian marine sponge Hyattella sp. J. Nat. Prod. 2010, 73, 985–987.
  46. Mudianta, I.W.; Skinner-Adams, T.; Andrews, K.T.; Davis, R.A.; Hadi, T.A.; Hayes, P.Y.; Garson, M.J. Psammaplysin derivatives from the Balinese marine sponge Aplysinella strongylata. J. Nat. Prod. 2012, 75, 2132–2143.
  47. Kurimoto, S.I.; Ohno, T.; Hokari, R.; Ishiyama, A.; Iwatsuki, M.; Omura, S.; Kobayashi, J.; Kubota, T. Ceratinadins E and F, new bromotyrosine alkaloids from an Okinawan marine sponge Pseudoceratina sp. Mar. Drugs 2018, 16, 463.
  48. Xu, M.; Andrews, K.T.; Birrell, G.W.; Tran, T.L.; Camp, D.; Davis, R.A.; Quinn, R.J. Psammaplysin H, a new antimalarial bromotyrosine alkaloid from a marine sponge of the genus Pseudoceratina. Bioorg. Med. Chem. Lett. 2011, 21, 846–848.
  49. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3–25.
  50. Christen, K.E.; Davis, R.A.; Kennedy, D. Psammaplysin F increases the efficacy of bortezomib and sorafenib through regulation of stress granule formation. Int. J. Biochem. Cell. Biol. 2019, 112, 24–38.
  51. Jiao, W.H.; Li, J.; Zhang, M.M.; Cui, J.; Gui, Y.H.; Zhang, Y.; Li, J.Y.; Liu, K.C.; Lin, H.W. Frondoplysins A and B, unprecedented terpene-alkaloid bioconjugates from Dysidea frondosa. Org. Lett. 2019, 21, 6190–6193.
  52. Kumar, R.; Bidgood, C.L.; Levrier, C.; Gunter, J.H.; Nelson, C.C.; Sadowski, M.C.; Davis, R.A. Synthesis of a unique psammaplysin F library and functional evaluation in prostate cancer cells by multiparametric quantitative single cell imaging. J. Nat. Prod. 2022, 83, 2357–2366.
  53. Malamas, M.S.; Sredy, J.; Moxham, C.; Katz, A.; Xu, W.; McDevitt, R.; Adebayo, F.O.; Sawicki, D.R.; Seestaller, L.; Sullivan, D.; et al. Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties. J. Med. Chem. 2000, 43, 1293–1310.
  54. Bhattarai, B.R.; Kafle, B.; Hwang, J.-S.; Khadka, D.; Lee, S.-M.; Kang, J.-S.; Ham, S.W.; Han, I.-O.; Park, H.; Cho, H. Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects. Bioorg. Med. Chem. Lett. 2009, 19, 6161–6165.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Pharmacology & Pharmacy
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Diaa T. A. Youssef
,
Lamiaa A. Shaala
View Times: 526
Revisions: 2 times (View History)
Update Date: 15 Nov 2022
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback